

## **Humabs BioMed CEO Filippo Riva Appointed to Swiss Biotech Association Board of Directors**

*Bellinzona (Switzerland), May 4, 2017* -- Humabs BioMed SA, a leading Swiss antibody therapeutics company, today announced that Filippo Riva, Chief Executive Officer and Chief Financial Officer, has been appointed to the Swiss Biotech Association Board of Directors.

“I am very pleased to have the opportunity to serve such a worthwhile organization,” said Filippo Riva, CEO & CFO of Humabs BioMed. “The Swiss Biotech Association has ongoing many activities to promote the biotechnology industry, increase understanding of the industry amongst policymakers and the general public and enhance awareness of the contributions our industry is making to find safer, more effective treatments for a wide range of diseases.”

The Swiss Biotech Association represents the interests of the biotech sector, supports the entrepreneurship of biotech companies and generates value for them through a variety of activities. These activities include representing the industry to policy makers; providing support for association members through education and professional development as well as assistance in securing financing; publicizing industry achievements and contributions to politicians and the general public and collaborating with strategic partners, including life sciences clusters and funding agencies, on both the national and international levels.

###

### *About Humabs BioMed SA*

Humabs BioMed, a private biotechnology company based in Switzerland, is focused on discovering and developing fully human monoclonal antibodies to treat serious infections. Humabs' proprietary discovery technology – CellClone – platforms enable the isolation of antibodies that have passed natural selection by the human immune system in response to disease and can generally be developed rapidly without extensive lead optimization. Humabs has a portfolio of more than a dozen immunotherapy product candidates. The Company has partnered several of its programs with MedImmune and Novartis, and two of these programs are now in clinical development by the partners. The Company is internally developing antibodies directed against hepatitis B virus and respiratory syncytial virus and metapneumovirus (RSV/MPV). These programs are currently in preclinical development. In collaboration with various public health agencies, Humabs is also developing a portfolio of immunotherapies against major public health threats, including MERS-CoV, Dengue, Ebola, Rabies and Zika viruses.

#### **Company Inquiries**

Humabs BioMed SA  
Filippo Riva, CEO & CFO  
Tel. +41 91 825 63 80  
info@humabs.com

#### **Media Inquiries**

MC Services AG  
Anne Hennecke  
Tel. +49-211-529252-22  
anne.hennecke@mc-services.eu

Laurie Doyle  
Tel. +1 339 832 0752  
laurie.doyle@mc-services.eu